9:00am - 5:00pm

Our Opening Hours Mon. - Fri.

1.800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors

Top West Virginia Mesothelioma Lawyer | Law Firm | Attorney | GPW > Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors

Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors

Estimated reading time: < 1 min

Condition: Metastatic Cancer

Estimated Enrollment: 424

Gender: All

Min Age: 18 Years

Age Group: Adult, Older Adult

Current Status: Recruiting

Study Results: No Results Available

Outcome Measures: Safety and Tolerability of INCB001158 as a single agent and in combination with Pembrolizumab: Incidence of Adverse Events,  Recommended Phase 2 Dose (RP2D) of INCB001158,  RP2D of INCB001158 with Pembrolizumab, Plasma pharmacokinetic (PK) profile of INCB001158 alone and in combination with Pembrolizumab

Interventions: INCB001158, Pembrolizumab

Phase:

Study Type: Interventional

Study Design: Allocation: Non-Randomized, Intervention Model: Factorial Assignment, Masking: None (Open Label),Primary Purpose: Treatment

Primary Completion Date: November 2019

Completion Date: April 2020

Last  Posted Date: July 15, 2019

Location: University of South Alabama, Mobile, Alabama, United States

Website Link: https://ClinicalTrials.gov/show/NCT02903914

Was this article helpful?
Dislike 0